International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
2022 · Blood · 2,486 citations
https://doi.org/10.1182/blood.2022015850
O
Olatoyosi Odenike
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
354
Papers
10.0K
Citations
46
h-index
135
i10-index
Olatoyosi Odenike is an academic researcher from University of Chicago. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Acute Lymphoblastic Leukemia research. The author has an h-index of 46, co-authored 301 publications.
ORCID: 0000-0002-4027-4124Papers by this author
worksInterim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
2013 · Journal of Hematology & Oncology · 94 citations
https://doi.org/10.1186/1756-8722-6-81
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
2021 · Journal of Clinical Oncology · 89 citations
https://doi.org/10.1200/jco.20.03420
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
2016 · Journal of Hematology & Oncology · 88 citations
https://doi.org/10.1186/s13045-016-0367-x
Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
2008 · Biology of Blood and Marrow Transplantation · 86 citations
https://doi.org/10.1016/j.bbmt.2008.08.004
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia
2016 · Leukemia & lymphoma/Leukemia and lymphoma · 74 citations
https://doi.org/10.3109/10428194.2015.1122781
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat